Ovarian Cancer Radiomics Approach in CT Led Evaluation

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorImperial College Healthcare NHS Trust

About this trial

When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment.

There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer.

This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.

Eligibility criteria

Qualifiers

Written (signed and dated) informed consent

Age 18 years or over

Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)

Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery

Disqualifiers

Known contra-indication to CT with IV contrast (e.g. contrast allergy, renal failure, inability to lie flat);

Unable to give informed consent;

Known pregnancy;

No visible disease <2cm on portal venous phase baseline CT scan;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

168 Participants
are grouped into 1 trial group

Sponsors and collaborators

Imperial College Healthcare NHS Trust

Lead sponsor

National Cancer Center, Korea

Collaborator